Compared to SR-BI-negative cells, the improved cellular uptake of DTX-sHDL nanoparticles in SR-BI-positive cells was verified by CLSM and FCM, confirming the higher targeting and anti-cancer abilities. Here, SCARB1 is linked to cancer.